07-08-2025
- Business
- Wall Street Journal
Liver Tumor Therapy Company HistoSonics Valued at $2.25 Billion in Sale
Investors have struck a deal to buy a majority stake in HistoSonics, valuing the company whose noninvasive therapy for liver tumors shows promise in other diseases at $2.25 billion.
An investor group acquired two-thirds of Plymouth, Minn.-based HistoSonics, which uses focused ultrasound to mechanically destroy and liquefy tumors.
